Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

393 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Convalescent Plasma Therapy in Immunocompromised Patients Infected With the BA.1 or BA.2 Omicron SARS-CoV-2.
Richier Q, De Valence B, Chopin D, Gras E, Levi LI, Abi Aad Y, Pacanowski J, Meynard JL, Plaçais L, Fey D, Couture P, Martin-Blondel G, Pestre V, Woessner J, Ancellin S, Weyrich P, Carpentier B, Idri S, Tiberghien P, Surgers L, Hueso T, Lacombe K. Richier Q, et al. Among authors: lacombe k. Influenza Other Respir Viruses. 2024 Mar;18(3):e13272. doi: 10.1111/irv.13272. Influenza Other Respir Viruses. 2024. PMID: 38501337 Free PMC article.
Convalescent plasma in patients receiving rituximab or ocrelizumab for multiple sclerosis or neuromyelitis Optica spectrum disorder with Covid-19: A multicenter retrospective study.
Dequidt T, Richier Q, Louapre C, Ader F, Merad Y, Lauwerier N, Jacomet C, Carles M, Biron C, Gendrin V, Marlat C, Danion F, Lepage TM, Sotto A, Bourdellon L, Mania A, Martinot M, Falher GL, Ferre A, Pilmis B, Gondran G, Simeone P, Henry M, Kamel T, Ray S, Ancellin S, Mélé N, Camou F, Destremau M, Sellenet J, Zucman N, Le Maréchal M, Mellouki K, Langlois ME, Luque Paz D, Mousset M, Leclerc C, Sommet A, Lacombe K, Martin-Blondel G. Dequidt T, et al. Among authors: lacombe k. Int J Infect Dis. 2025 Feb;151:107323. doi: 10.1016/j.ijid.2024.107323. Epub 2024 Dec 4. Int J Infect Dis. 2025. PMID: 39643155 Free article.
Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial.
de Truchis P, Assoumou L, Landman R, Mathez D, Le Dû D, Bellet J, Amat K, Katlama C, Gras G, Bouchaud O, Duracinsky M, Abe E, Alvarez JC, Izopet J, Saillard J, Melchior JC, Leibowitch J, Costagliola D, Girard PM, Perronne C; ANRS 162-4D Study Group. de Truchis P, et al. J Antimicrob Chemother. 2018 Mar 1;73(3):738-747. doi: 10.1093/jac/dkx434. J Antimicrob Chemother. 2018. PMID: 29186458 Clinical Trial.
Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials.
Siempos II, Kalil AC, Belhadi D, Veiga VC, Cavalcanti AB, Branch-Elliman W, Papoutsi E, Gkirgkiris K, Xixi NA, Kotanidou A, Hermine O, Porcher R, Mariette X; CORIMUNO-19 Collaborative Group; DisCoVeRy Study Group; ACTT-2 Study Group; ACTT-3 Study Group. Siempos II, et al. EClinicalMedicine. 2024 Feb 9;69:102472. doi: 10.1016/j.eclinm.2024.102472. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38361992 Free PMC article.
APOBEC-Induced Mutations at Initiation of Cabotegravir + Rilpivirine for Two Patients Infected by HIV-1 Subtype CRF02: The Interest of Systematic Genotyping.
Wembulua BS, Valin N, Lambert-Niclot S, Nerozzi-Banfi E, Chiarabini T, Meynard JL, Lacombe K. Wembulua BS, et al. Among authors: lacombe k. J Acquir Immune Defic Syndr. 2023 Mar 1;92(3):e17-e18. doi: 10.1097/QAI.0000000000003148. J Acquir Immune Defic Syndr. 2023. PMID: 36729654 No abstract available.
Same-day initiation of bictegravir/emtricitabine/tenofovir alafenamide: Week 48 results of the FAST study-IMEA 055.
Bachelard A, Isernia V, Charpentier C, Benalycherif A, Mora M, Donadille C, Duvivier C, Lacombe K, El Mouhebb M, Spire B, Landman R, Descamps D, Peytavin G, Assoumou L, Ghosn J; FAST study group. Bachelard A, et al. Among authors: lacombe k. J Antimicrob Chemother. 2023 Mar 2;78(3):769-778. doi: 10.1093/jac/dkad008. J Antimicrob Chemother. 2023. PMID: 36659824
Beta-variant recombinant SARS CoV-2 vaccine induces durable cross-reactive antibodies against Omicron BA variants.
Launay O, Gupta R, Machabert T, Konate E, Rousseau A, Vigne C, Beckers F, Devlin L, Botelho-Nevers E, Cachanado M, Chidiac C, Deplanque D, Dussol B, Ben Ghezala I, Lachatre M, Lacombe K, Laine F, Luong Nguyen LB, Pavese P, Schmidt-Mutter C, Tavolacci MP, Chicz RM, Coudsy B, Sridhar S, Touati A, Tartour E, Simon T. Launay O, et al. Among authors: lacombe k. Commun Med (Lond). 2025 Jan 18;5(1):21. doi: 10.1038/s43856-024-00675-9. Commun Med (Lond). 2025. PMID: 39827332 Free PMC article.
393 results